Recent advances in healthcare research have increasingly leveraged routinely collected administrative data to monitor cancer recurrence. This approach circumvents the delays and resource-intensive ...
WEST LAFAYETTE, Ind. — A Purdue University professor and several international researchers have developed a new method and algorithm that can predict the recurrence of prostate cancer in patients ...
Researchers have developed and validated a machine learning--based method to predict which patients with early-stage melanoma are most likely to experience a cancer recurrence. Most deaths from ...
EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4–Positive Solid Tumors, Including Metastatic Urothelial Carcinoma A prospective biomarker clinical trial was ...
Approximately 20% to 30% of men with prostate cancer experience disease recurrence within 5 years of therapeutic intervention. 1 A key challenge in managing these patients is a scarcity of accurate ...
STAFFORD, Texas, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, ...
Comparison of the efficacy between the gemcitabine/cisplatin (GP) and capecitabine/cisplatin (XP) for the advanced biliary tract cancer: Retrospective analysis in a single institution. Background: ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results